tetano
Editor, Senior Moderator
J Med Virol
. 2021 Jul 1.
doi: 10.1002/jmv.27172. Online ahead of print.
Immunostimulation with Interferon-γ in protracted SARS-Cov-2 pneumonia
Anne-Claire Lukaszewicz[SUP] 1 2 [/SUP], Fabienne Venet[SUP] 2 3 4 [/SUP], Alexandre Faure[SUP] 1 [/SUP], Emmanuelle Vignot[SUP] 5 [/SUP], Guillaume Monneret[SUP] 2 3 [/SUP]
Affiliations
Abstract
Deep immunosuppression is a major hallmark of COVID-19 patients with altered IFN-release, low monocyte HLA-DR expression (mHLA-DR), and profound lymphopenia accompanied by functional CD8+ T cell impairments. In this context, patients under chronic use of immunomodulatory therapeutics with pre-existent altered immune surveillance and defective anti-viral immunity may be at increased risk for protracted SARS-CoV-2 pneumonia. We report here COVID-19 pneumonia course in a 68-years-old female patient with rheumatoid arthritis chronically treated with rituximab (anti-CD20 monoclonal antibody). Due to rapid clinical deterioration and viral persistence despite convalescent plasma (CP) therapy, a treatment with IFN-γ was successfully instituted. This article is protected by copyright. All rights reserved.
Keywords: Antigen presentation < Immune responses; Immunodulators < Disease control; Immunomodulation < Immune responses; Inflammation < Immune responses; Interferon < Antiviral agents; SARS coronavirus < Virus classification.
. 2021 Jul 1.
doi: 10.1002/jmv.27172. Online ahead of print.
Immunostimulation with Interferon-γ in protracted SARS-Cov-2 pneumonia
Anne-Claire Lukaszewicz[SUP] 1 2 [/SUP], Fabienne Venet[SUP] 2 3 4 [/SUP], Alexandre Faure[SUP] 1 [/SUP], Emmanuelle Vignot[SUP] 5 [/SUP], Guillaume Monneret[SUP] 2 3 [/SUP]
Affiliations
- PMID: 34196421
- DOI: 10.1002/jmv.27172
Abstract
Deep immunosuppression is a major hallmark of COVID-19 patients with altered IFN-release, low monocyte HLA-DR expression (mHLA-DR), and profound lymphopenia accompanied by functional CD8+ T cell impairments. In this context, patients under chronic use of immunomodulatory therapeutics with pre-existent altered immune surveillance and defective anti-viral immunity may be at increased risk for protracted SARS-CoV-2 pneumonia. We report here COVID-19 pneumonia course in a 68-years-old female patient with rheumatoid arthritis chronically treated with rituximab (anti-CD20 monoclonal antibody). Due to rapid clinical deterioration and viral persistence despite convalescent plasma (CP) therapy, a treatment with IFN-γ was successfully instituted. This article is protected by copyright. All rights reserved.
Keywords: Antigen presentation < Immune responses; Immunodulators < Disease control; Immunomodulation < Immune responses; Inflammation < Immune responses; Interferon < Antiviral agents; SARS coronavirus < Virus classification.